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Background: Carotid endarterectomy (CEA) is the gold standard for the treatment of carotid stenosis, but carotid
angioplasty and stenting has been advocated in high-risk patients. The definition of such a population has been elusive,
particularly because the data are largely retrospective. Our study examined results for CEA in the National Surgical
Quality Improvement Program database (both Veterans Affairs and private sector).
Methods: National Surgical Quality Improvement Program data were gathered prospectively for all patients undergoing
primary isolated CEA during the interval 2000 to 2003 at 123 Veterans Affairs and 14 private sector academic medical
centers. Study end points included the 30-day occurrence of any stroke, death, or cardiac event. A variety of clinical,
demographic, and operative variables were assessed with multivariate models to identify risk factors associated with the
composite (stroke, death, or cardiac event) end point. Adjudication of end points was by trained nurse reviewers
(previously validated).
Results: A total of 13,622 CEAs were performed during the study period; 95% were on male patients, and 91% of cases
were conducted within the Veterans Affairs sector. The average age was 68.6  0.1 years, and 42.1% of the population
had no prior neurologic event. The composite stroke, death, or cardiac event rate was 4.0%; the stroke/death rate was
3.4%. Multivariate correlates of the composite outcome were (odds ratio, P value) as follows: deciles of age (1.13, .018),
insulin-requiring diabetes (1.73, <.001), oral agent–controlled diabetes (1.39, .003), decade of pack-years smoking
(1.04, >.001), history of transient ischemic attack (1.41, >.001), history of stroke (1.51, >.001), creatinine
>1.5 mg/dL (1.48, >.001), hypoalbuminemia (1.49, >.001), and fourth quartile of operative time (1.44, >.001).
Cardiopulmonary comorbid features did not affect the composite outcome in this model. Regional anesthesia was used
in 2437 (18%) cases, with a resultant relative risk reduction for stroke (17%), death (24%), cardiac event (33%), and the
composite outcome (31%; odds ratio, 0.69; P  .008).
Conclusions: Carotid endarterectomy results across a spectrum of Veterans Affairs and private sector hospitals
compare favorably to contemporary studies. These data will assist in selecting patients who are at an increased risk
for adverse outcomes. Use of regional anesthetic significantly reduced perioperative complications in a risk-adjusted
model, thus suggesting that it is the anesthetic of choice when CEA is performed in high-risk patients. ( J Vasc Surg
2006;43:285-96.)In the early 1990s, the landmark North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
and Asymptomatic Carotid Atherosclerosis Study (ACAS)
From the Division of Vascular and Endovascular Surgery,a Center for
Clinical Effectiveness in Surgery,b and Division of Cardiac Surgery,c
Massachusetts General Hospital, Boston, the University of Colorado
Health Outcomes Program,d and the Veterans Affairs Boston Healthcare
System, West Roxbury.e
Competition of interest: none.
Presented at the Fifty-Ninth Annual Meeting of the Society for Vascular
Surgery, Chicago, Ill, Jun 16-19, 2005.
Additional material for this article may be found online at www.mosby.
com/jvs.
Reprint requests: Michael C. Stoner, MD, Department of Surgery, Division
of Vascular and Endovascular Surgery, East Carolina University, Brody
School of Medicine, Greenville, NC 27834 (e-mail: stonerm@ecu.edu).
CME article
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.10.069trials were reported, and both confirmed the benefit of
carotid endarterectomy (CEA) for patients with carotid
artery stenosis vs medical therapy.1,2 With respect to symp-
tomatic lesions, the NASCET trial demonstrated an overall
stroke/death rate of 5.8% in CEA patients. The ACAS
study demonstrated a 2.3% perioperative stroke/death rate,
with a 50% relative risk reduction for stroke in patients with
a greater than 60% stenosis. Although most studies report
perioperative mortality andmajor adverse event rates in line
with, or better than, the pivotal randomized trials, there
have been several reports of divergent results based on
several possible variables, such as surgeon volume, institu-
tional practices, and operative technique.3-14 There is a body
of evidence demonstrating that operative outcome correlates
with a variety of patient factors, and, accordingly, better out-
comes can be expected with appropriate patient selection.
The recent Asymptomatic Carotid Surgery Trial demon-
strated a favorable outcome with CEA applied to a large
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caution that inappropriate patient selection may preclude
these benefits.15
With the advent of catheter-based carotid revascular-
ization, a new dimension has been added to the algorithm
of care for the patient with carotid stenosis. Carotid artery
stenting (CAS) is proposed to offer stroke reduction, with a
decrease in perioperative morbidity and mortality. A single
randomized study demonstrated a noninferiority for CAS
as compared with CEA in the high-risk patient,16 although
what precisely “high risk” entails remains controversial.9,17
Furthermore, with the low stroke or death rates quoted in
the literature, many studies are not significantly powered to
define variables associated with the high-risk population.
The goal of our study was to identify variables associated
Table I. Univariate analysis of major postoperative outcom
endarterectomy
Variable n Stroke
All patients 13,622 1.7%
Patient variables
Age 80 y
Yes 1341 1.6%
No 12,281 1.7%
Male
Yes 12,992 1.6%
No 630 2.7%†
Diabetes
Yes 3580 2.1%†
No 10,042 1.5%
Creatinine 1.5 mg/dL
Yes 1943 1.9%
No 11,679 1.6%
Smoker
Yes 5250 2.0%†
No 8372 1.5%
History of TIA
Yes 4243 2.7%*
No 9378 1.2%
History of CVA
Yes 2461 2.8%*
No 11,161 1.4%
Neurologic symptoms
Yes 5846 2.6%*
No 7776 1.0%
“High risk”
Yes 3544 1.7%
No 10,078 1.7%
Operative variables
General anesthesia
Yes 11,185 1.7%
No 2437 1.4%
Vascular surgeon
Yes 12,911 1.6%
No 711 2.5%
PGY 5 assistant
Yes 10,253 1.6%
No 3369 1.7%
TIA, Transient ischemic attack; CVA, cerebrovascular accident; PGY, postg
*P  .001.
†P  .05.
‡P  .01.with morbidity and mortality in the contemporary practice of CEA as recorded in the National Surgical Quality Im-
provement Program (NSQIP) database.
METHODS
Database. The NSQIP is a quality-improvement ini-
tiative that began at the Veterans Affairs (VA) health system
in 1994.18 The project was extended to the private sector
(PS) in 1999, starting with three academic medical cen-
ters.19 The NSQIP PS initiative has since been expanded to
14 different institutions (Appendix I, online only). The
Denver VA Medical Center NSQIP office and the Univer-
sity of Colorado Health Outcomes Program maintain both
the VA and PS databases and oversee the accrual of patient
data.
Data from patients undergoing surgery are prospec-
een in various subgroups undergoing carotid
th Cardiac event Stroke/death Composite
1.1% 3.4% 4.0%
* 1.2% 4.5%† 5.1%†
1.1% 3.2% 3.9%
1.1% 3.3% 3.9%
1.2% 3.8% 4.6%
† 1.6%‡ 4.6%* 5.5%*
1.0% 2.9% 3.4%
* 1.9%† 5.4%* 6.3%*
1.0% 3.0% 3.6%
1.1% 3.6% 4.2%
1.2% 3.2% 3.9%
* 1.1% 4.5%* 5.1%*
1.1% 2.8% 3.5%
* 1.5%† 5.3%* 6.1%*
1.0% 2.9% 3.5%
* 1.2% 4.6%* 5.2%*
1.1% 2.4% 3.1%
* 1.5%‡ 4.3%* 5.2%*
1.0% 3.0% 3.5%
1.2% 3.5%† 4.2%†
0.8% 2.5% 3.0%
1.1% 3.3% 4.0%
1.1% 3.8% 4.6%
† 1.1% 3.2% 3.8%
1.0% 3.9% 4.5%
te year.es s
Dea
2.0%
3.5%
1.9%
2.1%
1.3%
3.1%
1.6%
4.1%
1.7%
1.9%
2.1%
2.4%
1.8%
3.1%
1.8%
2.6%
1.6%
3.0%
1.7%
2.1%
1.6%
2.0%
2.1%
1.8%
2.5%
raduatively identified, randomly sampled, and entered into a
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PS. Baseline clinical, demographic, perioperative, and 30-
day postoperative data are collected from the medical
record, operative logs, and patient interviews. Postsurgical
data are obtained for the entire 30-day time period, regard-
less of whether the patient is discharged to the outpatient
setting before this time.
Case selection. Both the NSQIP VA and PS from the
years 2000 through 2003 were searched by using the
Common Procedural Terminology code 35301. Cases
were selected in which CEA was the primary procedure;
reoperative CEA and concurrent cardiac surgical proce-
dures were excluded. In addition, the remaining proce-
dure data were searched to ensure that no other major
Table II. Univariate analysis of postoperative complicatio
various subgroups undergoing carotid endarterectomy
Variable n Cardiova
All patients 13,622 1.6%
Patient variables
Age 80 y
Yes 1341 3.0%*
No 12,281 1.5%
Male
Yes 12,992 1.6%
No 630 1.9%
Diabetes
Yes 3580 1.9%
No 10,042 1.5%
Creatinine 1.5 mg/dL
Yes 1943 2.5%*
No 11,679 1.5%
Smoker
Yes 5250 1.4%
No 8372 1.8%
History of TIA
Yes 4243 2.1%†
No 9378 1.4%
History of CVA
Yes 2461 1.6%
No 11,161 1.6%
Neurologic symptoms
Yes 5846 1.8%
No 7776 1.5%
“High risk”
Yes 3544 2.3%*
No 10,078 1.4%
Operative variables
General anesthesia
Yes 11,185 1.6%
No 2437 1.5%
Vascular surgeon
Yes 12,911 1.6%
No 711 1.1%
PGY 5 assistant
Yes 10,253 1.5%‡
No 3369 2.0%
TIA, Transient ischemic attack; CVA, cerebrovascular accident; PGY, postg
*P  .001.
†P  .01.
‡P  .05.procedure was included.Demographics and preoperative variables. Basic de-
mographic information, including age, sex, and race, was
obtained. Age was considered as both a continuous and a
categorical variable in subsequent analysis. Hospital sites
were identified with unique numbers and coded for sector
(VA or PS). Clinical variables included in both the VA and
PS databases were considered (Appendix II, online only).
Age and pack-years of smoking were considered continu-
ous variables for the purpose of the multivariable analysis.
Of particular importance to CEA, data were obtained on
history of transient ischemic attacks, previous cerebrovas-
cular accident with symptoms, and cerebrovascular acci-
dent without symptoms. The NSQIP database does not
record the laterality of such neurologic symptoms. A variety
xcluding stroke, death, and major cardiac events) seen in
Pulmonary Surgical All morbidity
2.2% 0.8% 10.5%
4.0%* 1.2% 14.7%*
2.0% 0.8% 10.0%
2.3% 0.8% 10.5%
1.9% 2.0%* 10.5%
3.0%* 0.7% 11.7%†
2.0% 0.9% 10.1%
3.9%* 1.3%* 13.7%*
2.0% 0.7% 10.0%
2.1% 0.8% 10.5%
2.3% 0.8% 10.5%
2.7%‡ 0.9% 12.5%*
2.0% 0.8% 9.6%
3.8%* 0.8% 11.6%‡
1.9% 0.8% 10.2%
3.0%* 0.8% 12.2%*
1.7% 0.8% 9.2%
3.6%* 1.1%‡ 13.1%*
1.7% 0.7% 9.6%
2.3% 0.8% 10.9%*
1.8% 0.8% 8.5%
2.2% 0.8% 10.5%
3.2% 1.1% 10.8%
2.1% 0.7% 9.9%*
2.6% 1.0% 12.1%
te year.ns (e
scular
raduaof laboratory examinations were obtained as well, including
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lation profiles, serum electrolytes, albumin, liver enzymes,
and troponin. For the subsequent analysis, serum creatinine
and albumin were treated as both continuous and dichot-
omous variables. For subgroup analysis (Tables I and II),
SAPPHIRE risk factors were considered any of the follow-
ing: history of congestive heart failure, history of myocar-
dial infarction (available in the PS patient population),
presence of chronic obstructive pulmonary disease, or age
older than 80 years.16 Because of the limitations of the
NSQIP database, the local-anatomic risk factors included
by Yadav et al16 could not be used to create this subgroup,
and therefore this represents an approximation of the med-
ical comorbidities included in the authors’ “high risk”
definition.
Surgical variables. Surgical variables included the
American Society of Anesthesiologists class (treated as a
categorical variable), elective vs emergent case, anesthetic
technique, airway score, specialty of the primary surgeon,
level of training of the assistant surgeon (dichotomized as
postgraduate year 4 or 4), presence of an attending
surgeon, operative time, blood transfusion requirements,
and concurrent procedures.
Outcome variables. The primary outcome in this
study was the occurrence of a postoperative stroke, death,
or cardiac event. The NSQIP defines a postoperative stroke
as follows: the patient develops an embolic, thrombotic, or
hemorrhagic vascular accident or stroke with motor, sen-
sory, or cognitive dysfunction that persists for 24 or more
hours. A cardiac event was defined as a new Q-wave
myocardial infarction or cardiac arrest that necessitated
cardiopulmonary resuscitation. Cardiac isoenzyme de-
termination was not part of this routine data collection.
These primary end-point variables were also combined
into a composite outcome (stroke, death, or cardiac
event), because this is emerging as the convention for
describing postoperative outcomes in carotid stent–
based revascularization studies.16
Secondary end points were based on the incidence of
postoperative complications, exclusive of the primary end
points. Complications were classified into a systems-based
approach (Appendix III, online only). Finally, basic re-
source utilization data were examined. The total length of
stay and postoperative length of stay were derived on the
basis of the admission, operative, and discharge dates as
recorded in the database.
Statistical analysis. Patients were stratified according
to the primary outcome variables: stroke, death, cardiac
event, and the composite variable. Univariate analysis was
conducted by using a 2 or Student t test to compare
patients who incurred one of the primary outcome events vs
those who were unaffected. This univariate process was also
undertaken for the secondary (complication) variables.
With respect to the composite outcome, multivariable lo-
gistic regression analysis was performed to identify inde-
pendent associations with clinical covariates. Candidate
variables for inclusion in the model were selected from
those significant to P  .10 for the primary outcomes byusing stepwise selection with entry and stay criteria of .10
and .05, respectively. Continuous variables were also as-
sessed as categorical (deciles or quintiles) or binary variables
to assess the linearity of the association. Complete case
analysis was performed, with the exception of continuous
variables with nontrivial numbers of missing data, for which
the mean value was substituted for the missing value and a
binary missing marker was generated (with 1 for missing
and 0 for nonmissing values). Stepwise selection using
entry and stay criteria of .10 and .05, respectively, was
performed, with manual oversight of each step. The model
was assessed by using the Hosmer-Lemeshow goodness-
of-fit test and with the c-statistic. Additional multivariable
models were also constructed for each of the primary
outcome variables (stroke, death, or cardiac event) by using
Table III. Demographics and preoperative and operative
characteristics of the study population
Variable Data
Demographics
No. patients 13,622
Mean age (y) 68.5  0.1
Age 80 y 1341 (9.8%)
Age range (y) 33-103
Male 12,992 (95.4%)
White 10,862 (83.4%)
Hospital
Private sector 1192 (8.8%)
Inpatient 12,430 (90.8%)
Clinical
Diabetic: insulin 1163 (8.2%)
Diabetic: oral agents 2417 (17.7%)
Alcohol use 1130 (8.3%)
Smoker 5250 (38.5%)
Smoking history (pack-years) 42.1  9.6
History of TIA 4243 (31.2%)
History of stroke, no deficit 1219 (8.6%)
History of stroke, with deficit 2461 (18.1%)
Dialysis 58 (0.4%)
COPD 2094 (15.4%)
Dyspnea 2365 (17.4%)
CHF 334 (2.5%)
Poor functional status 759 (5.6%)
Laboratory
Hematocrit (%) 40.6  1.1
Platelet count (1000/mL) 237  17.4
Creatinine (mg/dL) 1.2  0.1
Albumin (g/dL) 3.9  0.1
Operative
Emergency 182 (1.3%)
ASA class III 2025 (14.9%)
General anesthesia 11,185 (82.1%)
Bleeding 4 units 42 (0.3%)
Vascular surgeon staff 12,911 (94.8%)
Attending present 13,560 (99.5%)
PGY 5 assistant 10,253 (75.3%)
Operative time (h) 2.5  0.1
TIA, Transient ischemic attack; COPD, chronic obstructive pulmonary
disease; CHF, congestive heart failure; ASA, American Society of Anesthe-
siologists; PGY, postgraduate year.
All values are SE.methods similar to those described previously.
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stratified by significant variables were calculated by using
the multivariable models described previously. These mod-
els then predicted the likelihood of the outcome for each
individual according to his or her other risk factors, and the
sum of these probabilities was used to calculate the ex-
pected number of events. Asymmetric 95% confidence lim-
its for the observed-expected ratio were calculated by using
the method described by Breslow and Day.20
The analysis was generated with SAS software, version
8.02 (SAS Institute Inc, Cary, NC). The Institutional
Review Board of the Massachusetts General Hospital ap-
proved the conduct of this study.
RESULTS
During the study period, 13,622 isolated CEAs were
identified, and clinical and demographic data are described
in Table III. Most of these cases were undertaken at the VA
health system (91.2%), and correspondingly 95.4% of the
cases were in male patients. Patients in this study demon-
strated significant comorbidities. Most patients (57.9%)
had a history of stroke or transient ischemic attack. With
respect to the 30-day primary outcomes, the stroke, death,
cardiac event, and composite (stroke, death, or cardiac
event) event rates were 1.7%, 2.0%, 1.1%, and 4.0%, respec-
tively (Table IV). The stroke or death rate was 3.4%. The
total complication rate was 10.5%. The average total length
of stay was 3.3  1.6 days, with an average postoperative
stay of 2.1  1.1 days.
Univariate analysis for the major outcome variables is
displayed in Table I. Age, diabetes mellitus (DM), renal
Table IV. Major and minor 30-day outcomes in the
population undergoing carotid endarterectomy
Variable n % Mean Range
Major outcome
Stroke 226 1.7
Death 274 2.0
Stroke/death 458 3.4
Cardiac event 153 1.1
Composite 543 4.0
Postoperative complications
Cardiovascular 222 1.6
Neurologic 180 1.3
Surgical 111 0.8
Infectious 127 0.9
Thrombotic 17 0.1
Pulmonary 305 2.2
Renal/urinary 24 0.1
Other complications 733 5.4
Total complications 1429 10.5
Utilization
LOS mean (d) 3.3  1.6
LOS range (d) 0-372
POS mean (d) 2.1  1.1
POS range (d) 0-180
LOS, Length of stay; POS, postoperative stay.
All values are SE.insufficiency, and cerebrovascular symptoms were all signif-icantly associated with the composite end point. The high-
risk subgroup (based on SAPPHIRE medical inclusion
criteria) demonstrated a significantly higher mortality, car-
diac event rate, and composite outcome rate. The use of a
regional anesthetic was found to be protective for the
composite outcome (Fig). Univariate analysis of cardiovas-
Fig. Observed-expected ratios for anesthetic modality (shaded
bar, general anesthesia [GA]; open bar, local anesthesia [LA]) vs
each major outcome. *P  .01.
Table V. Multivariate correlates predictive of the
composite outcome (stroke, death, or cardiac event)
Variable
Odds
ratio
95%
Confidence
limits P value
Patient variables
Age (10 y) 1.130 1.002-1.023 .018
Diabetic: insulin 1.734 1.336-2.250 .001
Diabetic: oral agents 1.390 1.119-1.727 .003
Smoking (pack-years) 1.040 1.002-1.006 .001
COPD 1.235 0.989-1.544 NS
History of TIA 1.411 1.179-1.688 .001
Stroke with deficit 1.507 1.235-1.839 .001
Creatinine 1.5 mg/dL 1.478 1.209-1.807 .001
Albumin 0.671 0.539-0.835 .001
Operative variables
Emergency 1.958 1.170-3.274 .010
ASA class 1.339 1.111-1.614 .002
General anesthesia 1.414 1.093-1.829 .008
Bleed 4 units 11.11 5.574-22.174 .001
Fourth quartile of OR time 1.440 1.179-1.759 .001
COPD, Chronic obstructive pulmonary disease; NS, not significant; TIA,
transient ischemic attack; ASA, American Society of Anesthesiologists; OR,
operating room.
c-index  0.67; Hosmer-Lemeshow P  .28.cular, pulmonary, and surgical complications and total
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insufficiency, cerebrovascular symptoms, anesthetic choice,
and assistant training level affected the total complication
rate and several other classes of adverse events.
Candidate variables from the univariate analysis of
composite outcome were selected and used to construct a
multivariate model (Table V). Age, DM, pack-years of
smoking, presence of symptomatic cerebrovascular disease,
renal insufficiency, hypoalbuminemia, emergent operation,
American Society of Anesthesiologists class, prolonged op-
erative time, and significant bleeding all portended a higher
risk for occurrence of the composite outcome. An addi-
tional multivariate analysis was constructed to model stroke
or death, the traditional end point in surgical carotid liter-
ature (Table VI). Use of a general anesthetic also negatively
affected this composite outcome (odds ratio, 1.414; Table
V and Fig). Univariate analysis of patient characteristics
stratified by anesthetic type demonstrated that whereas
regional anesthetic was more commonly used for older
patients, those with dyspnea, a smoking history, and neu-
rologic symptoms were more commonly handled with a
general anesthetic (Table VI).
DISCUSSION
A review of the recent literature demonstrates a rather
admirable postoperative stroke or death rate after CEA.6-14
These relatively low stroke or death incidences compound
the difficulty in defining the high-risk patients, even in
rather large series. This particular dilemma (defining and
dealing with the high-risk carotid patient) continues to
evolve in this era of carotid stenting.
By using the best medical therapy of the time as a
control, the landmark NASCET and ACAS trials showed
Table VI. Multivariate correlates predictive of stroke
or death
Variable
Odds
ratio
95%
Confidence
limits P value
Patient variables
Age (10 y) 1.180 1.020-1.340 .024
Diabetes 1.487 0.837-2.641 NS
Smoking (pack-years) 1.004 1.001-1.007 .011
COPD 1.155 0.894-1.493 NS
History of TIA 1.507 1.169-1.942 .001
Stroke with deficit 1.734 1.314-2.288 .001
Creatinine 1.5 mg/dL 1.667 1.245-2.233 .001
Albumin 0.684 0.525-0.890 .005
Operative variables
Emergency 2.237 1.080-4.631 .030
ASA class 1.203 0.925-1.564 NS
General anesthesia 1.684 1.158-2.447 .006
Bleed 4 units 16.05 5.885-43.772 .001
Fourth quartile of OR time 1.523 1.145-2.026 .003
COPD, Chronic obstructive pulmonary disease; NS, not significant; TIA,
transient ischemic attack; ASA, American Society of Anesthesiologists; OR,
operating room.
c-index  0.69; Hosmer-Lemeshow P  .60.operative risks of 5% and 3% for symptomatic and asymp-tomatic patients, respectively.1,2 Because of these low ad-
verse event rates, large-sample-size studies are required to
identify factors associated with an adverse outcome. A
description of the high-risk patient can come only from
suitably powered studies.
The surgical literature has traditionally considered
stroke and death to be the two major adverse events asso-
ciated with CEA. The inclusion of cardiac events in this
outcome variable is based on evidence that nonfatal myo-
cardial injury has a significant and severe effect on patient
survival.21,22 In addition, it seems that even clinically insig-
nificant myocardial injury (troponin leak) has a deleterious
effect on survival.22 It is this realization—that even rela-
tively innocuous cardiac events profoundly affect survival—
that has propelled the definition of our composite out-
come, which is also shared by the emerging carotid stent
literature.16 Our definition of a cardiac event, which is
limited by the NSQIP database, will capture only major
events and, therefore, may only approximate other defini-
tions in the literature.
Advanced age was a powerful predictor of postopera-
tive complications. Age has been well documented as an
independent risk factor for perioperative mortality in both
vascular and nonvascular surgery.23 Some authors have
suggested that careful selection based on comorbidities and
functional status can be used to offset the effects of increas-
ing age.24-26 The NSQIP database used by this study
records, among other salient variables, the functional status
of the patients. However, functional status failed to reach
statistical significance at the univariate level and did not
meet criteria for inclusion into the multivariate analysis.
The fact that poor functional status was a negative prog-
nostic factor in our recent NSQIP abdominal aortic aneu-
rysm study, but not in this analysis, suggests that the
magnitude of the operation explains the importance of a
patient’s functional status.27 Similar to our results, others
have also raised questions regarding the safety of CEA in
the elderly.28,29 A subgroup analysis of the recent Asymp-
tomatic Carotid Surgery Trial failed to demonstrate a stroke
risk–reduction benefit in patients 80 years and older.15 In
addition, the randomizedCarotidRevascularization andEnd-
arterectomy vs Stent Trial has identified a higher risk in pa-
tients more than 80 years of age undergoing carotid artery
angioplasty and stenting.30 These data, both the findings in
the CAS literature and this study, reinforce the need for
careful, appropriate patient selection when carotid revascu-
larization is considered in the elderly.
It is well documented that CEA risk can be stratified by
a patient’s preoperative neurologic status.7,31 The fact that
operative risk is higher in this set of patients is generally
offset by the powerful benefit of CEA in this group.1,32
Most patients in this study had a prior neurologic event,
and we have demonstrated an overall stroke or death rate of
3.4%. This finding alone is encouraging and demonstrates
that in contemporary practice, the operative risk of CEA is
within the guidelines previously published, even for pa-
tients with symptomatic carotid disease.33
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risk factor for postoperative complications. A recent NSQIP-
based study demonstrated that the presence of insulin-treated
DM was a significant independent risk factor for a poor
outcome after major vascular surgery.34 However, with re-
spect to CEA, the role of DM as a contributor to perioper-
ative risk is disputed. Although some authors have demon-
strated that patients with DMwho present for CEA are not
at an increased risk,9,35,36 several others support the role of
DM as an independent risk factor.37,38 In addition, al-
though outside the scope of this study, DM has been impli-
cated as a risk factor for post-CEA intracranial hemorrhage
and recurrent carotid stenosis.39,40 The NSQIP project sepa-
rates DM into insulin-requiring and non–insulin-requiring
disease. Our multivariate analysis for the composite adverse
outcome demonstrated stratification based on insulin-
treated and non–insulin-treated DM. In fact, the presence
of insulin-treated DM was found to be the strongest inde-
pendent patient risk factor for an adverse outcome on the
basis of an increased risk of cardiac events and death in this
group. DM was not found to be an important correlate of
stroke or death in the multivariate model (Table VI). This
finding suggests that cardiac risk stratification is appropriate
in higher-risk diabetic patients. However, the overall low
rate of major cardiac complications justifies operation with-
out formal cardiac testing for the majority of diabetic and
nondiabetic patients.
Evaluation of a given patient’s nutritional status is a
complex process with a variety of anthropometric and
biochemical markers. Poor nutritional status is well recog-
nized as a negative factor in recovery from operation and
wound healing. Assessment of nutritional status in this
elderly population is appropriate, given the high incidence
of malnutrition in patients with advanced age.41 With
respect to the variables collected in this study, serum albu-
min is a reasonable measure of overall nutritional status and
anabolic capacity. Low serum albumin has been cited as a
marker for poor postoperative outcome and impaired
wound healing by a series of authors.42-45 This was verified
in this study by a finding that an increase in serum albumin
was protective with respect to the incidence of a major
adverse event. Although this information has been demon-
strated for several other operations, this is the first study we
are aware of that has examined nutritional status and CEA.
Smoking history, as measured by pack-years, did signif-
icantly affect outcome in a predictable manner. Countless
studies have implicated both the direct pulmonary effects of
tobacco smoke and its systemic atherogenic properties as
negative influences on postoperative outcome.46 Increased
serum creatinine, indicating renal impairment, was also a
strong predictor of the composite outcome by multivariate
analysis. Examination of the univariate data demonstrated a
significant increase in both cardiac events and mortality
in patients with a serum creatinine level greater than
1.5 mg/dL. Renal insufficiency has been well described as
a negative prognostic factor in patients undergoing vascular
operations.47-52 A recent report suggests that a threshold of
renal function can be used to stratify patients toward oper-ative vs medical treatment of carotid stenosis.53 In addition,
renal insufficiency has been noted to be an independent
predictor of mortality in patients with vascular disease.54
This fact suggests that careful analysis is required when
CEA is undertaken in patients with renal insufficiency to
ensure that they will live long enough to benefit from
revascularization, and this is especially true in the asymp-
tomatic patient. Just as suggested by the presence of DM,
careful cardiac risk stratification is warranted in these pa-
tients.
Using a risk-adjusted multivariate analysis, our study
demonstrated a significant decrease in the composite out-
come when a regional anesthetic technique was used (Table
V; Fig). Although level 1 evidence is lacking, the use of a
regional anesthetic has long been advocated as a means for
risk reduction in patients undergoing CEA, and this is
the current practice at our institution for high-risk pa-
tients.55-57 Thus far, support for this stance has been
based on small trials and retrospective reviews, and a
recent meta-analysis proved to be inconclusive in this re-
gard.58 Improved outcomes can be ascribed to the lack of
hemodynamic lability, improved cerebral perfusion, and
blunted myocardial stress.59-61 In this study, general anes-
thesia seemed to be favored in patients with prior stroke,
transient ischemic attack, dyspnea, or poor functional sta-
tus. This most likely indicates the preserved difficulty of
operating on these patients without a controlled airway
(Table VII). Still, a relatively high proportion of our pa-
tients underwent CEA with a regional anesthetic (17.9%),
which demonstrates the applicability of the technique
across institutions. Our findings, obtained from a prospec-
tive multicenter risk-adjusted database, support the use of
local anesthesia in the high-risk surgical patient, and this is
similar to the selective practice of endoluminal therapy
based on risk stratification.
The secondary end point of this study was a description
of the postoperative 30-day morbidity related to CEA. We
found a total complication rate of 10.5%, which, compared
with previously published large series, is quite high.7,11,13
This likely relates to the methodical data collection and
follow-up by the NSQIP. It is appreciated that traditional
retrospective studies tend to underreport complications:
the true numbers are cited as being 2 to 4 times higher.62
With respect to possible predictive factors for complica-
tions, age, DM, renal insufficiency, tobacco use, cerebro-
vascular symptoms, and use of a general anesthetic were all
significant at the univariate level. This overall complication
rate is in line with other NSQIP studies and represents an
accurate value, which should be part of any operative
decision process.
There are inherent limitations to this study. This is the
first report of a combined VA and PSNSQIP project. There
are obvious systemwide differences between the VA and the
PS institutions. Although the overwhelming majority of
patients in our study were from the VA sector, we believed
that it was important to demonstrate the applicability of a
combined database. This also prompted us to examine
possible outcome discrepancies between the two sectors.
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significant difference between the VA and PS with respect
to a risk-adjusted composite outcome. The database used in
this study does not record specific cardiac risk variables,
such as recent myocardial infarction or the presence of
angina. In fact, the presence of congestive heart failure is
the only cardiac preoperative variable available, and there-
fore the role of cardiac risk factors is likely underestimated
in our analysis. It is also likely that the true incidence of
cardiac events was underestimated because of the lack of
minor cardiac event variables in the database. In addition,
the NSQIP project is based on the identification of risk
factors for perioperative adverse events. Because of this, we
are unable to comment on the true risk reduction from
future stroke or improved life expectancy. Although they
were collected prospectively, these data were not obtained
with the specific aim of analyzing outcomes after CEA.
Accordingly, variables specific to carotid artery surgery,
such as reconstructive technique, shunt use, reversal of
anticoagulation, and cranial nerve injury, are not part of this
Table VII. Univariate analysis of patient characteristics str
Variable
General
n %
Demographics
Patients 11,185 100
Mean age (y)
Age 80 y 1033 9.2
Male 10,739 96.0
White 8939 83.8
Clinical
Diabetic: insulin 965 8.6
Diabetic: oral agents 1999 17.9
Alcohol use 946 8.5
Smoker 4426 39.6
Smoking history (pack-years) 41.7  0.4
History of TIA 3581 32.0
History of stroke, no deficit 1029 9.2
History of stroke, with deficit 2068 18.4
Dialysis 46 0.4
COPD 1740 15.6
Dyspnea 1983 17.9
CHF 262 2.3
Poor functional status 643 5.7
Laboratory
Hematocrit (%)
Platelet count (1000/mL)
Creatinine (mg/dL)
Albumin (g/dL)
Operative
Emergency 160 1.4
ASA class III 1691 15.1
Bleeding 4 units 31 0.3
Vascular surgeon staff 2293 94.0
Attending present 11,127 99.4
PGY 5 assistant 8337 74.5
Operative time (h) 2.5  0.1
COPD, Chronic obstructive pulmonary disease; CHF, congestive heart fail
PGY, postgraduate year.
All values are SE.data set. Also, the database lacks local-anatomic risk factorssuch as prior cervical surgery, radiotherapy, high-carotid
bifurcation, contralateral carotid status, and the presence of
intracranial vascular disease. Because of this, our comments
as to the high-risk population are limited tomedical factors;
a more specific database is required to address these specific
factors. In addition, formal neurologic examination is not
part of the NSQIP definition of stroke, and therefore this
adverse outcome is likely underestimated by this study.
Finally, the NSQIP database does not record the laterality
of neurologic symptoms or CEA, and, therefore, it is im-
possible to derive the exact number of patients with symp-
toms referable to carotid stenosis.
These data have identified medical variables that con-
tribute to complications after CEA and should aid decision-
making when carotid interventions are undertaken in high-
risk patients. It is important to note that the use of a
regional anesthetic is an easily applied process that can
diminish major complications after surgical revasculariza-
tion of carotid stenosis in a high-risk patient. Further
randomized trials are required to examine the role of anes-
d by anesthetic modality
Regional
P valueMean n % Mean
2437 100
1  0.1 69.4  0.1 .001
308 12.6 .001
2253 92.5 .001
1924 81.5 .100
198 8.1 .060
418 17.2 .100
184 7.6 .136
824 33.8 .001
38.4  0.8 .011
662 27.1 .001
190 7.8 .027
393 16.1 .006
10 0.4 .994
354 14.5 .200
382 15.7 .001
72 2.9 .076
116 4.8 .001
6  0.1 39.9  0.1 .001
6  0.7 231  1.4 .040
2  0.1 1.2  0.1 .146
9  0.1 3.8  0.1 .001
22 0.9 .039
334 13.7 .075
11 0.4 .158
10,618 95.0 .091
2433 99.8 .018
1916 78.6 .001
2.1  0.1 .001
IA, transient ischemic attack; ASA, American Society of Anesthesiologists;atifie
68.
40.
23
1.
3.
ure; Tthetic modality with respect to CEA operative risk and
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Volume 43, Number 2 Stoner et al 293outcomes. Finally, these data will contribute to the emerg-
ing trials and literature on the appropriate application of
carotid angioplasty and stenting.
Supplementary data
Additional material for this article may be found online
at www.jvascsurg.org.
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Dr Enrico Ascher (Brooklyn, NY). If you were to diminish
the mortality in this group of patients, what factors would you use
to improve your selection criteria, particularly in asymptomatic
patients?
Dr Stoner. Much of these data come from our univariate
analysis. We looked back at the multivariate findings and found
that increasing age was very important for 30-day mortality.
Dr Ascher. What was the age limit?
Dr Stoner.We used an age greater than 80 years. We did find
that that was a very significant and independent factor for 30-day
mortality.
Dr Ascher. You’re talking about mortality only, right?
Dr Stoner. Yes, 30-day mortality. In addition, our anesthetic
findings were very powerful in terms of factors which surgeons can
directly influence in patient selection and so forth.
Dr Peter Schubart (San Jose, Calif). With respect to your
findings about anesthesia, is there a benefit of cervical block
anesthesia or a risk of general anesthetic? Was there any group of
patients that had both? If so, did they act like the patients with
cervical block anesthesia or the patients with general anesthetic?
Dr Stoner.Unfortunately, the way the NSQIP methodology
is designed, once a patient has a general anesthetic, all other
anesthetic record is sort of removed. So the general anesthetic takesto answer that question. These data are not intention to treat and
are rather “yes or no” general anesthetic.
Dr Mark Fillinger (Lebanon, NH). In terms of regional vs
general anesthetic, no randomized prospective study has ever
shown a difference in terms of stroke and death rates, cardiac issues,
or even silent cardiac ischemia. The NSQIP is directed toward
hospitals, more so than individuals, with better observed vs ex-
pected outcomes. I was wondering if you had any data that might
help us determine whether this suggested anesthetic effect may be
related to individual surgeons who might have a better surgical
technique or individual institutions with a worse general anesthetic
technique, different patient populations, etc. Further multivariate
analysis would certainly be helpful.
Dr Stoner.We looked at this indirectly in a very gross manner.
We compared anesthetic technique issues between the sectors,
those being the private sector and the VA health care sector. And in
that analysis, we didn’t see a difference between the two sectors.
We did not undertake a volume-based analysis in this study, but it
is planned in a future study.
Dr Julie Ann Freischlag (Baltimore, Md). As you know, one
of the benefits of the NSQIP data is when you do have an unusual
observed-to-expected (O/E) ratio that is an outlier, then you’re
able to look at that and then follow that up in the next year. In the
VA system, many improvements were then made as people saw
JOURNAL OF VASCULAR SURGERY
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were an outlier for wound infection, then in the next year many
times, in fact almost all the time, we found centers moved back into
a more expected O/E ratio.
So my question to you is, did you have an opportunity to look
at this along the time, so that you could see whether or not some of
these effects actually go away? Which would be if somebody did
notice that their O/E ratio for the anesthesia was an outlier in
general anesthesia, I would predict that it would come back within
a normal O/E ratio, with people knowing that. So my question
is, have you done that? And if not, I think it would be a great
thing to do.
Dr Stoner. We did examine the use of anesthetic technique
over the study time period and did not see any trends. At this time,
I’m not aware if the NSQIP committee within the VA sector is
aware of this finding. We will make our findings available internally
first and then in our manuscript. But clearly that’s the mission and
the mechanism by which the NSQIP operates, which is a
continued evolution of care processes. And I think we’ve iden-
tified a significant care process which can be modified to im-
prove outcome.
Dr George Lavenson (Visalia, Calif). This information,
showing the lowest stroke and death rate currently obtainable with
carotid endarterectomy, is particularly important at this time when
new modalities, such as stenting, are being justified by comparison
with historical and overall surgical results instead of the best that
can be obtained with surgery. All are not the same: both Health
Grades and Money Magazine did note surgeons and institutions
with best results in carotid endarterectomy.
My question is regarding the exact technique and the specific
methods used during endarterectomy by those in your study with
the best results. We were included in Health Grades and Money
Magazine and have a less than 1% stroke/mortality rate. Our
method uses local anesthesia, and only 5% of the patients need a
shunt. Consequently, we are able to purposively keep our arteriot-
omy in the wider more proximal portion of the internal carotid
artery and free and remove the lesion with final cleaning with loop
magnification from within. This has the advantage of the eversion
technique but without the need to transect. There is less need of a
patch and less early postoperative thrombosis. I would appreciate
any information in your series regarding results as related to carotid
endarterectomy techniques.
Dr Stoner.Certainly it’s been the practice of our vascular unit
at the MGH [Massachusetts General Hospital] to employ selective
use of regional anesthetic selected by anatomic criteria and patient
criteria. And we agree with your statement.
However, within the NSQIP database we presented from
today, the resolution does not exist to answer that question. This
data, as sorted by CPT [Common Procedural Terminology] code,
contained essentially all carotid endarterectomies, regardless of
technique and shunt use, which again are not part of this database.
And maybe those questions can be answered as our society is now
rolling out a carotid database based on the NSQIP methodology,
and perhaps this more specialized version of the database will
answer those sort of questions.
unanswered.Dr Piergiorgio Cao (Perugia, Italy). Thank you very much
for providing very important information on the risk factors for
carotid endarterectomy.
I don’t know if I missed the information, but it seems that
coronary artery disease was not a predisposing risk factor for
complication. The presence of coronary disease is very important.
Were you able to grade the severity of coronary artery disease or to
analyze the subgroup with more severe disease predisposed to a
higher risk factor for surgery?
Dr Stoner. The short answer to your question is no. The
current version of the database that we presented today does not
have those data.
And the NSQIP database is a bit of a moving target. The
private sector version of the database, which is essentially the
next-generation version compared to what’s employed at the VA,
does stratify out risk factors such as prior coronary angioplasty and
stenting, history of angina, and history of coronary artery disease.
The data presented today from this 2000 to 2003 time period
include only the presence of congestive heart failure as a coronary
marker in the preop patients, and that’s a rather gross marker. So
those data do not exist in the current version of the database
presented today.
Dr Michael Golden (Philadelphia, Pa). I rise to merely com-
ment that I agree with the authors’ data that there is a benefit for
carotid endarterectomy patients from local/regional anesthesia
over general anesthesia. I also find that there is an additional
benefit from this that may not be reflected in your data. When
patients consider the options available to them for repair of their
carotid lesions, great emphasis has been placed on carotid artery
stenting. When carotid endarterectomy can be provided without a
general anesthetic and with no longer hospital stay than for stent-
ing, patients become much more receptive to the idea of surgery
rather than gravitating directly toward stenting alone.
Dr Stoner. That’s true. And I think that the assumption from
that is that by identifying that local regional anesthetic technique is
protective in our model, essentially we will be able to provide
carotid endarterectomy with a cardiac risk profile similar to what
we see in carotid angioplasty and stenting. And I think it’s very
important for surgeons to keep it in our armamentarium, as carotid
therapy is an evolving target. Carotid stenting seems to have
raised the bar a bit in terms of postoperative coronary compli-
cations, and surgery needs to be able to reach that bar to remain
the gold standard.
Dr Frank LoGerfo (Boston, Mass). To say that regional
anesthesia is protective is really going beyond your data. You don’t
know the fate of those patients who had regional anesthesia but
were converted to general anesthesia, because general anesthesia
trumps that in your data set. And as you point out in your own
institution, you use regional anesthesia selectively, depending on
the patient characteristics. So you can say there’s a difference in
your selective practice, but you cannot say regional anesthesia is
protective.
Dr Stoner.Within the confines of our multivariate model and
speaking purely from a statistical point of view, a general anesthetic
was an independent risk factor. But without the randomized
prospective trial, which is ongoing in the UK right now, it is
impossible to definitively state that, I agree.INVITED COMMENTARYTimothy F. Kresowik, MD, Iowa City, Iowa
After surviving earlier attacks on its efficacy through the
conduct of well-designed randomized trials, carotid end-
arterectomy (CEA) is again being challenged by the purported
“less-invasive” alternative of carotid artery stenting (CAS).
The study by Stoner et al provides important data for the
current debate but has limitations that leave many questionsThe SAPPHIRE trial injected the issue of cardiac morbidity
into the CEA vs CAS debate. Perioperative cardiac events can be
compared between studies only if similar, standardized protocols
are used for surveillance for myocardial damage. Unfortunately,
the National Surgical Quality Improvement Program database
includes only Q-wave myocardial infarction (a small subset of all
perioperative myocardial infarctions). However, the observation in
this study that local or regional anesthesia was associated with
better outcomes at least raises the question of whether the differ-
ences in cardiac morbidity seen in the SAPPHIRE trial were
anesthetic rather than procedure related.
An important issue often neglected in the CEA vs CAS debate
is whether neurologically asymptomatic, medically high-risk pa-
tients are likely to benefit from either procedure. The relatively
benign natural history of asymptomatic carotid stenosis established
in the Asymptomatic Carotid Atherosclerosis Study trial should
not be forgotten. The limitations of the National Surgical Quality
Improvement Program database with regard to the collection of
specific cardiac risk factors such as prior myocardial infarction or
the presence of angina limit the usefulness of this study in guiding
the selection of neurologically asymptomatic patients who are
more likely to benefit fromCEA.Many of the risk factors identified
in this study (diabetes, age, and smoking) are surrogate markers for
coronary artery disease. A specific cardiac history combined with
noninvasive cardiac screening of selected individuals is likely a
more important risk assessment approach for the practicing sur-
geon than using the risk factors identified in this study alone.
Clinical studies like this one are as important as randomized
trials in establishing the efficacy of procedures. Community-wide
studies are necessary to demonstrate that the procedural outcomes
observed in a randomized trial can be achieved across the entire
spectrum of patients likely to undergo the procedure and physi-
cians likely to perform the procedure. This study adds to the
literature that supports the fact that CEA can be performed across
this spectrum with perioperative adverse event rates comparable to
those achieved in the randomized trials. It remains to be seen
whether this will be as true for CAS as it is for CEA.
JOURNAL OF VASCULAR SURGERY
February 2006296 Kresowik
Appendix I, online only. The 14 participating academic
medical centers in the National Surgical Quality
Improvement Program private sector
Brigham & Women’s Hospital
Columbia University
Cornell University
Emory University
Massachusetts General Hospital
Saint Louis University
University of California, San Francisco
University of Florida
University of Kentucky
University of Maryland
University of Michigan
University of Utah
University of Virginia
Washington University
Appendix II, online only. Selected preoperative clinical
variables shared between the Veterans Affairs and private
sector National Surgical Quality Improvement Program
database
Race
Smoking history
Pack-years smoking
Diabetes
Chronic obstructive pulmonary
disease
Dyspnea
Congestive heart failure
Ascites
Poor functional status
Concurrent cancer
Dialysis
Prior radiotherapy
Bleeding disorder
Delirium
Evidence of infection
History of stroke
History of transient ischemic attack
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Appendix III, online only. Classification system for postoperative complications
Category Complications
Cardiovascular Cardiac event not defined as a myocardial infarction or cardiac arrest
Neurologic Nonstroke central nervous system event
Surgical Return to the operating room for any reason
Postoperative bleeding necessitating blood transfusion
Peripheral nerve injury manifesting as motor, sensory, or mixed motor/sensory defect
Graft failure and/or thrombosis
Wound dehiscence with fascial disruption
Infectious Systemic sepsis with evidence of infection and response
Wound infection in accordance with CDC criteria
Urinary tract infection diagnosed via microbiology or urinary symptoms in the setting of fever
Thrombotic Deep venous thrombosis based on clinical, radiographic, or ultrasonographic diagnosis
Pulmonary embolism diagnosed via ventilation-perfusion scan or computed tomography
Pulmonary Failure to wean from ventilator 48 h
Pneumonia diagnosed by physical examination, microbiology, or chest radiography
Renal/urinary Reintubation for any reason in the postoperative period
Renal failure necessitating dialysis
Renal insufficiency (serum creatinine 2.0 mg/dL)
Other Noninfectious urinary complication
Adverse event not described above
CDC, Centers for Disease Control.
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